Skip to main content
SpringerLink
Log in

Hormones exogènes et risque de cancer du sein : où en est-on ?

Exogenous hormones and breast cancer risk: where are we?

  • Conference paper
Acquis et limites en sénologie / Assets and limits in breast diseases

  • 222 Accesses

Résumé

Le cancer du sein est multifactoriel. Parmi les facteurs de risque, certains sont de niveau élevé comme les facteurs génétiques, la radiothérapie thoracique et la densité mammaire élevée.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Cummings SR, Tice JA, Bauer S et al. (2009) Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 101: 384–398

    Article  PubMed  Google Scholar 

  2. Bray F, Ren JS, Masuyer E, Ferlay J (2012) Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer [Epub ahead of print]

    Google Scholar 

  3. Rossouw JE, Prentice R (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288: 321–333

    Article  PubMed  CAS  Google Scholar 

  4. Foidart JM, Desreux J, Pintiaux A, Gompel A (2007) Hormone therapy and breast cancer risk. Climacteric 10(Suppl 2): 54–61

    Article  PubMed  CAS  Google Scholar 

  5. Fournier A, Berrino F, Clavel-Chapelon F (2008) Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat 107: 103–111

    Article  PubMed  CAS  Google Scholar 

  6. Lyytinen H, Pukkala E, Ylikorkala O (2009) Breast Cancer Risk in Postmenopausal Women Using Estradiol-Progestogen Therapy. Obst Gynecol 113: 65–73

    Google Scholar 

  7. de Lauzon-Guillain B, Fournier A et al. (2009) Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Generale de l’Education Nationale (E3N) cohort. Diabetologia 52: 2092–2100

    Article  PubMed  Google Scholar 

  8. Santen RJ, Yue W, Heitjan DF (2012) Modeling of the Growth Kinetics of Occult Breast Tumors: Role in Interpretation of Studies of Prevention and Menopausal Hormone Therapy. Cancer Epidemiol Biomarkers Prev [Epub ahead of print]

    Google Scholar 

  9. Kerlikowske KCA, Buist DS, Cummings SR, Vachon C, Vacek P, Miglioretti DL (2010) Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 28: 3830–3837

    Article  PubMed  Google Scholar 

  10. Gompel A, Santen RJ (2012) Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 15: 241–249

    Article  PubMed  CAS  Google Scholar 

  11. Caan B, Habel L, Quesenberry C, Kushi L, Herrinton L (2008) Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 100: 597–598; author reply 9

    Article  PubMed  Google Scholar 

  12. DeSantis C, Howlader N, Cronin KA, Jemal A (2011) Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev 20: 733–739

    Article  PubMed  Google Scholar 

  13. Farhat GN, Walker R, Buist DS, Onega T, Kerlikowske K (2010) Changes in invasive breast cancer and ductal carcinoma in situ rates in relation to the decline in hormone therapy use. J Clin Oncol 28: 5140–5146

    Article  PubMed  Google Scholar 

  14. Cibula D, Gompel A, Mueck AO et al. (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16: 631–650

    Article  PubMed  CAS  Google Scholar 

  15. Backman T, Rauramo I, Jaakkola K et al. (2005) Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 106: 813–817

    Article  PubMed  Google Scholar 

  16. Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA (2008) Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil Steril 90: 17–22

    Article  PubMed  CAS  Google Scholar 

  17. Lyytinen HK, Dyba T, Ylikorkala O, Pukkala EI (2010) A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Intern J Cancer 126: 483–489

    Article  CAS  Google Scholar 

  18. Dinger J, Bardenheuer K, Minh TD (2011) Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 83: 211–217

    Article  PubMed  CAS  Google Scholar 

  19. Plu-Bureau G, Lê MG S-WR, Thalabard JC, P. M-J (1994) Progestogen use and decreased risk of breast cancer in a cohort study of premenopausal women with benign breast disease. Br J Cancer 70: 270–277

    Article  PubMed  CAS  Google Scholar 

  20. Fabre A, Fournier A, Mesrine S et al. (2007) Oral progestagens before menopause and breast cancer risk. Br J Cancer 96: 841–844

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de gynécologie endocrinienne, Port-Royal-Cochin, APHP, Université Paris-Descartes, 75014, Paris, France

    A. Gompel

Authors
  1. A. Gompel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag France, Paris

About this paper

Cite this paper

Gompel, A. (2013). Hormones exogènes et risque de cancer du sein : où en est-on ?. In: Acquis et limites en sénologie / Assets and limits in breast diseases. Springer, Paris. https://doi.org/10.1007/978-2-8178-0396-8_17

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0396-8_17

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0395-1

  • Online ISBN: 978-2-8178-0396-8

Publish with us

Policies and ethics

Search

Navigation